Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Aclaris Therapeutics (ACRS) has provided an update.
Aclaris Therapeutics has struck a lucrative deal with OMERS, selling a portion of its future royalty payments and associated milestones from its license with Eli Lilly for OLUMIANT, a treatment for alopecia areata. The transaction nets Aclaris an immediate $26.5 million, with the potential for an additional $5 million, depending on sales achievements in 2024. OMERS, in return, gains a slice of the ongoing royalty pie from global sales of OLUMIANT, reinforcing its investment portfolio in the healthcare sector. This strategic financial move was also publicized through a press release to keep investors informed.
For an in-depth examination of ACRS stock, go to TipRanks’ Stock Analysis page.